SantPChawlaMD

Oncology • Santa Monica, CA

Sarcoma

Physician

Join to view full profile

Dr. Chawla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chawla's full profile

Already have an account?

Office
2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
Phone+1 310-552-9999

Fax+1 310-552-9999

Summary

Sant P. Chawla, M.D. is one of the world’s authorities in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. Dr. Chawla heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and conducts groundbreaking clinical research in pancreatic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer and gastrointestinal tumors.

Dr. Chawla serves on the clinical faculty of numerous prestigious cancer centers, including UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital; he has been an adjunct associate professor at Stanford University and is an adjunct associate professor at the University of Texas, M.D. Anderson Cancer Center; and he is a medical oncologist at Cedars Sinai Comprehensive Cancer Center. Over his 30 years of medical and clinical research experience, Dr. Chawla’s research has been a foundation for further breakthroughs in cancer treatment.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
All India Institute of Medical SciencesClass of 1977

Certifications & Licensure

CA State Medical License 1988 - 2026
TX State Medical License 1984 - 2025
IA State Medical License 1986 - 1990
MD State Medical License 1982 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study Using Rexin-G for Breast Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study Using Rexin-G for Sarcoma Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Phase II Study of Intravenous Rexin-G in Osteosarcoma Start of enrollment: 2007 Dec 01
Completed
Phase 2
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies Start of enrollment: 2007 Dec 01
Completed
Phase 1
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
Terminated
Phase 2, Phase 3
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
Active, not recruiting
Phase 2
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 2
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Apr 01
Completed
Phase 1
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Jan 11
Completed
Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Start of enrollment: 2013 Sep 24
Completed
Phase 1, Phase 2
LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14
Terminated
Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Completed
Phase 2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors Start of enrollment: 2014 Aug 01
Completed
Phase 1
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma Start of enrollment: 2014 Sep 02
Completed
Phase 1, Phase 2
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Start of enrollment: 2016 Feb 10
Completed
Phase 2
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Start of enrollment: 2016 Apr 27
Completed
Phase 1
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer Start of enrollment: 2017 May 04
Completed
Phase 1
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer Start of enrollment: 2018 May 09
Completed
Phase 2
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma Start of enrollment: 2020 Jan 03
Active, not recruiting
Phase 2
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma Start of enrollment: 2019 May 15
Recruiting
Phase 2
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Completed
Phase 1
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 Start of enrollment: 2022 Dec 12
Withdrawn
Phase 1, Phase 2
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma Start of enrollment: 2020 Aug 14
Recruiting
Phase 2
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Start of enrollment: 2021 Sep 09
Recruiting
Phase 2
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Start of enrollment: 2020 Sep 30
Recruiting
Phase 2
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Start of enrollment: 2023 Sep 01
Not yet recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board.
Sant P Chawla, Brian VAN Tine, Noah Federman, Joseph Schwab, Robin Jones
Anticancer Research. 2024-07-01
Editorial: Celebrating the 200th mendel's anniversary: gene-targeted diagnostics and therapies for cancer.
Noah Federman, Erlinda M Gordon, Sant P Chawla, Frederick L Hall
Frontiers in Molecular Medicine. 2024-01-01
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healt...
Richard T Kenney, John K Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham
Frontiers in Immunology. 2024-01-01

Lectures

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient surv...
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

BriaCell Begins Phase 1/2 Trial of Bria-OTS™ for Breast CancerNovember 21st, 2024
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer StudyNovember 21st, 2024
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialDecember 10th, 2020
Join now to see all